Polymer-free amphilimus-eluting stents vs. biodegradable-polymer everolimus-eluting stents in all-comers undergoing pci: 2-year results of the PARTHENOPE trial

View at publisher Summarise with VIRAT
Authors: Giovanni Esposito, Raffaele Piccolo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Over the past few decades, percutaneous coronary intervention (PCI) has undergone significant advancements as a result of the combination of device-based and drug-based therapies. These iterations have led to the development of polymer-free drug-eluting stents. However, there is a scarcity of data regarding their clinical performance on the long-term follow-up. Purpose To report the long-term follow-up of a randomized trial comparing polymer-free vs. biodegradable-polymer drug-eluting stents in patients undergoing PCI. Methods The PARTHENOPE trial was a phase IV, prospective, randomized, multicenter, investigator-initiated, assessor-blind study, which was conducted at 14 centers in Italy (NCT04135989). Nearly unselected patients undergoing PCI were randomly assigned to polymer-free amphilimus-eluting stents or biodegradable polymer everolimus-eluting stents. The primary endpoint was the composite of cardiovascular death, target-vessel myocardial infarction, or target-lesion revascularization. Primary analyses were done in the intention-to-treat population. The non-inferiority between the two study devices was already shown at 1-year follow-up. Herein, we provided the final follow-up at 2 years. Results Between Jan 22, 2020 and June 22, 2022, 2,107 patients with 3,042 coronary lesions were randomized to polymer-free amphilimus-eluting stents (1,051 patients) or biodegradable polymer everolimus-eluting stents (1,056 patients). Most (1,607 or 76.3%) patients presented with acute coronary syndrome. At 2-year follow-up, the primary endpoint occurred in 106 (10.1%) patients randomized to polymer-free amphilimus-eluting stents and 112 (10.6%) patients randomized to biodegradable polymer everolimus-eluting stents (hazard ratio, HR, 0.96, 95% confidence intervals, CIs, 0.73 to 1.25, p=0.741). There were no differences in the components of the primary endpoint, including cardiovascular death (HR 1.08, 95%CI to 1.66), target-vessel myocardial infarction (HR 0.94, 95%CI 0.65-1.36), and clinically-indicated target-lesion revascularization (HR 0.90, 95%CI 0.52-1.56). Results for the primary endpoint were consistent across several prespecified subgroups. Conclusions In allcomers undergoing PCI, polymer-free amphilimus-eluting stents were associated with a similar clinical performance in comparison to biodegradable polymer everolimus-eluting stents at 2-year follow-up.

Fields of Study & Subjects

Coronary Interventions and Diagnostics Antiplatelet Therapy and Cardiovascular Diseases Cardiac Imaging and Diagnostics

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Publication date
1 March 2026
Language
EN